Sucampo Initiates Enrollment for Phase II Liver Cirrhosis Trial
Posted on: Tuesday, 29 July 2008, 09:00 CDT
Sucampo Pharmaceuticals has enrolled its first patient in a single-center Phase II trial evaluating its clinical stage compound, cobiprostone, for the treatment of portal hypertension in patients with liver cirrhosis.
The Phase II double-blinded, randomized, placebo-controlled study will assess cobiprostone's safety and efficacy in treating portal hypertension. The study plans to enroll approximately 30 patients at the University of Texas Southwestern Medical Center in Dallas.
The primary efficacy endpoint is the change from baseline in hepatic venous pressure gradient (HVPG) following 28 days of study treatment.
Secondary endpoints include acute changes in HVPG following initial dosing with cobiprostone, as well as changes in other markers of liver disease and patient-reported quality of life measures.
Sucampo's cobiprostone is also in clinical development for the treatment of gastrointestinal ulcers in patients treated with prescription non-steroidal anti-inflammatory drug therapy. To date, cobiprostone has been evaluated in two Phase I trials in healthy volunteers, and in three Phase II proof-of-concept trials.
Ryuji Ueno, chairman and CEO of Sucampo, said: "Approximately one-third of deaths in patients with cirrhosis are caused by esophageal variceal bleeding due to portal hypertension. We believe that cobiprostone may lessen portal vein pressure and may reduce the likelihood of variceal bleeding."
Source: Datamonitor
Related Articles
- Sciele Pharma Announces That Addrenex Pharmaceuticals Initiates Phase II Clinical Trial of ADX415 for the Treatment of Hypertension
- Icagen Announces Initiation of Phase I Study of ICA-105665, a Novel Compound for the Treatment of Epilepsy
- Merrimack Pharmaceuticals Initiates Enrollment in a Phase 2 Study of MM-093 in Patients With Rheumatoid Arthritis
- XTL Announces the Completion of Phase I Study With XTL-6865 in Patients With Chronic Hepatitis C
- Amarillo Biosciences Announces Open Enrollment in Its Phase 2 Study of Orally Administered Interferon Alpha in the Treatment of Oral Warts in HIV-Positive Patients
- ViroPharma and Wyeth Initiate Dosing in Phase 2 Study of HCV-796 in Treatment Naive Patients and Non-Responders
- TorreyPines Therapeutics Completes Second Phase I Study for NGX267, a Selective M1 Agonist for the Treatment of Alzheimer's Disease
- Threshold Pharmaceuticals Completes Enrollment in a Phase 2 Study for the Treatment of Benign Prostatic Hyperplasia
- Xanthus Initiates a Phase 2 Study Of Xanafide in Combination With Ara-C for Treatment Of Secondary AML
- ChemGenex to Initiate Phase II Study With Quinamed in Prostate Cancer; Anti-Cancer Activity Observed in Recently Completed Phase I Study
 |
 |
User Comments (0)
RSS Feeds